𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells

✍ Scribed by Atsushi Ono; Kazuteru Kono; Dai Ikebe; Akihiko Muto; Jiying Sun; Masao Kobayashi; Kazuhiro Ueda; Junia V. Melo; Kazuhiko Igarashi; Satoshi Tashiro


Book ID
102220843
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
380 KB
Volume
46
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACH2 is a B‐cell‐specific transcription repressor and is also know as a tumor suppressor in B cell malignancy. Expression of BACH2 is induced in BCR‐ABL positive lymphoid cell lines including BV173 by imatinib, a molecular targeting agent for the treatment of chronic myeloid leukemia (CML). Here we show that the activity of the BACH2 gene is related to the nuclear positioning of the gene loci. We examined the spatial association of the BACH2 gene with the centromeric heterochromatin, a transcriptionally repressive subnuclear compartment, by comparing cells with low (BV173 and K562) and high (NAMALWA) levels of BACH2 mRNA. The BACH2 gene was located closer to the centromeric heterochromatin in BV173 and K562 cells as compared to NAMALWA cells. In BV173 cells, the BACH2‐centromere distance increased after imatinib treatment to levels similar to those in NAMALWA cells. We also found that diethylmaleate, an oxidative stressor, enhanced the antiproliferative effect of imatinib in only BV173 cells. Since BACH2 induces apoptosis by oxidative stress, these observations suggest that down‐regulation of the BACH2 gene through the interaction with centromeric heterochromatin would take part in leukomogenesis of BCR‐ABL positive lymphoid leukemia. © 2006 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Factors influencing the false positive a
✍ Andrew Chase; Francis Grand; Ji-Guang Zhang; Nicolas Blackett; John Goldman; Myr 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

BCR-ABL fluorescence in situ hybridization has a useful role to play in experimental and clinical investigations of chronic myeloid leukaemia. However, the interpretation of results is complicated by variability in the false positive rate (FPR) and false negative rate (FNR). We therefore examined th